Galecto Expected Upcoming Milestones; Top-Line Results From Phase 2b GALACTIC-1 Trial In Mid-2023; Interim Safety Data From Phase 2a GALLANT-1 Trial By Q1 2023; Initiation Of Phase 2 Investigator-Initiated GB1211 Oncology Trial in 2023
Galecto Expected Upcoming Milestones; Top-Line Results From Phase 2b GALACTIC-1 Trial In Mid-2023; Interim Safety Data From Phase 2a GALLANT-1 Trial By Q1 2023; Initiation Of Phase 2 Investigator-Initiated GB1211 Oncology Trial in 2023
Galecto預計即將到來的里程碑；2023年年中2b期Galaxy-1試驗的主要結果；2023年第一季度2a期GARANT-1試驗的臨時安全數據；2023年啟動由調查員發起的第二階段GB1211腫瘤學試驗
Expected Upcoming Milestones
預期即將到來的里程碑
- Top-line results from Phase 2b GALACTIC-1 trial (IPF) in mid-2023.
- Interim safety data from Phase 2a GALLANT-1 trial (NSCLC) by Q1 2023.
- Initiation of Phase 2 investigator-initiated GB1211 oncology trial (melanoma and HNSCC) by Providence Cancer Institute in 2023.
- 2023年年中2b期銀河1號試驗(IPF)的主要結果。
- 到2023年第一季度2a期GARANT-1試驗(NSCLC)的臨時安全數據。
- 普羅維登斯癌症研究所於2023年啟動由研究人員發起的2期GB1211腫瘤學試驗(黑色素瘤和HNSCC)。
"The recent release of positive results from two clinical trials, our Phase 1b/2a GULLIVER-2 trial in decompensated liver cirrhosis and our Phase 2a MYLOX-1 trial in myelofibrosis, has created significant momentum for Galecto and our team," said Galecto CEO Hans T. Schambye, M.D., Ph.D. "Galectin-3 and LOXL2 play a central role in fueling key pathological pathways in fibrosis, and the encouraging results from both of these trials provides further evidence and strengthens our belief that the inhibition of galectin-3 and LOXL2 are crucial to reducing fibrosis and potentially modifying disease. We look forward to 2023, where we expect to announce top-line results from our Phase 2b GALACTIC-1 trial in idiopathic pulmonary fibrosis (IPF) in mid-2023 and our Phase 2a GALLANT-1 trial in non-small cell lung cancer (NSCLC) in the second half of 2023."
Galecto公司首席執行官漢斯·T·尚拜博士説：“最近公佈的兩項臨牀試驗的陽性結果，即我們治療失代償性肝硬變的1b/2a期Gulliver-2試驗和我們治療骨髓纖維化的2a期MYLOX-1試驗，為Galecto公司和我們的團隊創造了巨大的動力。”Galectin-3和LOXL2在促進纖維化的關鍵病理途徑方面發揮着核心作用，這兩個試驗的令人鼓舞的結果提供了進一步的證據，並堅定了我們的信念，即抑制Galectin-3和LOXL2對於減少纖維化和潛在地改善疾病至關重要。我們期待着2023年，屆時我們預計將在2023年年中宣佈我們治療特發性肺纖維化(IPF)的2b期Galaxy-1試驗的主要結果，並在2023年下半年宣佈我們治療非小細胞肺癌(NSCLC)的2a期Galant-1試驗的主要結果。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。